Oracyn Oral News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2021 Financial Results
 | 
0 
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care,
eye, oral and nasal care and dermatological conditions today announced financial results for fiscal year 2021 and the fourth quarter ended March 31, 2021.
“For the past 18 months we have been restructuring the Company to cut losses while positioning it for growth,” said Amy Trombly, CEO. “Last year we consolidated all manufacturing at our factory in
Mexico (June), and ended our contract with Invekra that required us to sell product with low margin (October). This year, we entered into a partnership agreement with EMC Pharma, LLC for the sale ....

United States , New Zealand , Hong Kong , Testsieger Finanztest , Gabriel Science , Te Arai Biofarma Ltd , Sonoma Pharmaceuticals Inc , Cpharmaceuticals Aktie , Exchange Commission , Sonoma Pharmaceuticals , Vetsynova Co , Nasocyn Nasal Care , Oracyn Oral , Middle East , Quarter Ended March , Latin America , Year Ended March , Private Securities Litigation Reform , Ended March , ஒன்றுபட்டது மாநிலங்களில் , புதியது ஜீலாந்து , ஹாங் காங் , கேப்ரியல் அறிவியல் , தே அராய் உயிர் பார்மா லிமிடெட் , சோணோமா மருந்துகள் இன்க் , பரிமாற்றம் தரகு ,